Profound Medical Corp. (PROF) Financial Ratios

Profound Medical Corp. (PROF) has an ST Score of 53.8 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate PROF a Buy, with a price target of $11.00 (+85.8% vs the current price). Our ST Score grades it B- (53.8/100). The ST Score is a data-driven signal, not a recommendation.

Valuation B-, Profitability D-, Financial Strength A, Momentum B-, Growth B-, Forecast A-.

Profound Medical Corp. (PROF) earns a valuation grade of B-, measured against Medical - Devices peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Profound Medical Corp. (PROF) earns a growth grade of B-, measured against Medical - Devices peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Profound Medical Corp. (PROF) earns a profitability grade of D-, measured against Medical - Devices peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Profound Medical Corp. (PROF) earns a financial strength grade of A, measured against Medical - Devices peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Profound Medical Corp. (PROF) is $11.00 from 7 analysts, which is +85.8% versus the recent price of $5.92.

Profound Medical Corp. (PROF) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.